
Shares of U.S. telehealth firm Hims and Hers Health HIMS.N fall 7.11% to $21.81 premarket
U.S. FDA Commissioner Marty Makary said on Thursday that the regulator would take action against companies that mass-market "illegal copycat drugs" by claiming they are similar to FDA-approved products
HIMS began offering a cheaper $49 compounded version of Novo Nordisk's NOVOb.CO new Wegovy weight-loss pill
In 2025, HIMS shares gained 34.28%